Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. November 2022 08:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022

KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer...
02. November 2022 09:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient

KNOXVILLE, TN, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) has...
25. Oktober 2022 06:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation

KNOXVILLE, TN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with James G. Krueger, MD, PhD, Co-director,...
29. September 2022 06:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing

KNOXVILLE, TN, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Amina El Ayadi, PhD, Assistant...
21. September 2022 06:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Exclusive License Option Agreement with Ophthalmic Biophysics Center of Bascom Palmer Eye Institute at University of Miami for Treatment of Eye Infections

KNOXVILLE, TN, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has entered into an option agreement with the University of Miami (UM) for an exclusive...
24. August 2022 09:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent

KNOXVILLE, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department...
17. August 2022 07:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor,...
19. Juli 2022 06:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair

KNOXVILLE, TN, July 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Kelly Tseng, PhD, Associate Professor of...
30. Juni 2022 13:42 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress

KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to...
23. Juni 2022 09:41 ET | Quelle: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio

KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’ Board of Directors (Board) to seek...

Vorherige Seite